Aro Biotherapeutics

Unlocking the Potential of Genetic Medicines

[Aro Biotherapeutics @AroBioTx]

We are honored to have Sue Dillon, our Co-Founder and CEO, recognized as one of the top 20 women blazing trails in biopharma R&D

https://t.co/I5SAzETkM2

[Aro Biotherapeutics @AroBioTx]

We are honored to have @OTSociety highlight our company, leaders and lead program, ABX1100, for the potential treatment of Pompe Disease!

#ots #oligonucleotide #Aro #geneticdiseases #pompe #sirna #centyrins

https://t.co/BmKsEApZdX

[Chardan @ChardanCM]

Panelists include Tom Barnes, PhD, CEO, @Orna_TX; Susan Dillon, PhD, President & CEO, @AroBioTx; David Lockhart, PhD, President & CSO, @ReCodeTx; & Brian McVeigh, Chairman, CEO, & Co-Founder, @CodeBioTx. #ChardanGMConf #CGMC2022 #GeneticMedicines

[Aro Biotherapeutics @AroBioTx]

We are excited to announce that the FDA has granted Rare Pediatric Drug Designation for ABX1100, our lead program in Pompe Disease!

https://t.co/eQt6T4cO5Y

[Aro Biotherapeutics @AroBioTx]

We are excited to announce that the FDA recently has granted Orphan Drug Designation for ABX1100, our lead program in Pompe disease #Aro #PompeDisease #RareDisease #oligonucleotides #Centyrin #Pompe

https://t.co/Rie6nf2LZ7

[Aro Biotherapeutics @AroBioTx]

Join us TODAY at 2pm at TIDES USA 2022 in Boston as our Co-founder & CSO, Karyn ONeil, gives her talk on exciting progress of our lead program. Make sure to reach out if you there! #Aro #PompeDisease #RareDisease #oligonucleotides #Centyrin

https://t.co/YEb25C0wUm

[Aro Biotherapeutics @AroBioTx]

We are very excited to announce the expansion of both our team and our space!

https://t.co/r4aBmyMMs8

[Aro Biotherapeutics @AroBioTx]

Aro is excited to welcome Adam Dinerman and Zhonghao Liu to our leadership team!
https://t.co/HugOQVulNr

[Aro Biotherapeutics @AroBioTx]

Have you seen our newly redesigned website? You can check out open positions at https://t.co/fhakA3b0mj

[Jeff Cranmer @jeff_cranmer]

A $1.4B bio-$ deal w/@ionispharma sparked @AroBioTx's $88M series A. @BioCentury's mysterious @_Ktktktktk chats w/ CEO & $JNJ vet Sue Dillon on why Aro backburned cancer for orphan muscle disease & an autoimmune disorder, growing her team & what's next https://t.co/4mRzlK5VJu

[University City @ucdphl]

Another University City company making waves in the biotech realm! Congratulations to @AroBioTx, based out of @CICPhilly, for raising $88 million toward bringing its line of RNA-based drugs to market: https://t.co/uonTL1GZ5L

[Aro Biotherapeutics @AroBioTx]

Find our article in Endpoints featuring Aro's Co-Founders Sue Dillon and Karyn O'Neil:
https://t.co/I6n5Ezf7Un

[Technical.ly @Technical_ly]

We've spotted leadership and funding news in the first few days of the new year for @bftp_sep @TELABioInc @AroBioTx + @CarismaTherape1 https://t.co/lJBIleY9ZM

[Shaan Gandhi @shaangandhi]

Welcome @AroBioTx to the @npv_vc family! Looking forward to working with Sue Dillon and the team to make #centyrin technology a reality for #RNA therapeutics!

@Cowen_Inc @HealthCapVC #BVFPartners #RidgebackCapital @JNJInnovation @BioMotiv @ionispharma

https://t.co/StbwuWwvFr

[Amber Tong @AmberTongPW]

Can a new protein bring RNA drugs where they can't reach? J&J vet Sue Dillon's Ionis-partnered biotech gets $88M to prove yes - https://t.co/74U1Aa5xWr

[Aro Biotherapeutics @AroBioTx]

Check out our feature in today's Philadelphia Inquirer
https://t.co/Un8rMTi1FH

[Aro Biotherapeutics @AroBioTx]

Aro is excited to announce our Series A financing to advance the development of Centyrin-based therapies!
https://t.co/6E8itZE31b

[Aro Biotherapeutics @AroBioTx]

Aro Collaboration with Ionis Advances with Option Exercise $IONS

https://t.co/PSuMSomJGb